ArriVent BioPharma, Inc. (AVBP) bonds
AVBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$10.69−0.87 (-7.53%)
Close on Nov 17, 2026Market cap $527.10MP/E –Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
ArriVent BioPharma reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Notes and loans outstanding
As tagged in ArriVent BioPharma's 10-Q for the period ended Jun 30, 2026
ArriVent BioPharma's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size | Drawn |
|---|---|---|
| Loan and security agreement, Silicon Valley Bank | $15.00M | $0 |
See a number that looks wrong?